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AbstrAct
The Faculty of Intensive Care Medicine and Intensive Care 
Society Guideline Development Group have used GRADE 
methodology to make the following recommendations for 
the management of adult patients with acute respiratory 
distress syndrome (ARDS). The British Thoracic Society 
supports the recommendations in this guideline. 
Where mechanical ventilation is required, the use of 
low tidal volumes (<6 ml/kg ideal body weight) and 
airway pressures (plateau pressure <30 cmH2O) was 
recommended. For patients with moderate/severe ARDS 
(PF ratio<20 kPa), prone positioning was recommended 
for at least 12 hours per day. By contrast, high frequency 
oscillation was not recommended and it was suggested 
that inhaled nitric oxide is not used. The use of a 
conservative fluid management strategy was suggested 
for all patients, whereas mechanical ventilation with 
high positive end-expiratory pressure and the use of the 
neuromuscular blocking agent cisatracurium for 48 hours 
was suggested for patients with ARDS with ratio of arterial 
oxygen partial pressure to fractional inspired oxygen (PF) 
ratios less than or equal to 27 and 20 kPa, respectively. 
Extracorporeal membrane oxygenation was suggested as 
an adjunct to protective mechanical ventilation for patients 
with very severe ARDS. In the absence of adequate 
evidence, research recommendations were made for the 
use of corticosteroids and extracorporeal carbon dioxide 
removal.
IntroductIon
Aims
The purpose of this guideline is to provide an 
evidence-based framework for the manage-
ment of adult patients with acute respiratory 
distress syndrome (ARDS) that will inform 
both key decisions in the care of individual 
patients and broader policy. Our recommen-
dations are neither dictates nor standards of 
care. We cannot take into account all of the 
features of individual patients and complex 
local factors; all we can do is to synthesise rele-
vant evidence and to put it into the context 
of current critical care medicine. Similarly, 
our recommendations are not comprehen-
sive: these guidelines have relevance to a frac-
tion of the total number of decisions that are 
required of carers for these complex patients. 
Indeed, the current state of the art for the 
management of ARDS has been recently 
reviewed1–4 and comparable guidelines have 
been produced by national and international 
stakeholders.5 6
scope
The topics considered were chosen by the 
Guideline Development Group (GDG) in the 
light of results from a survey carried out for 
the Intensive Care Society (ICS), including 
556 responses from 3200 members. Popular 
topics were excluded by the GDG if it was felt 
that there was a dearth of evidence (eg, appro-
priate diagnostic investigations and the role 
of specialist centres), when the evidence was 
not specific to ARDS (weaning from mechan-
ical ventilation, nutrition and the timing of 
tracheostomy) and if there was overlap with 
existing guidelines (post-ICU (intensive care 
unit) care and rehabilitation).
definitions
ARDS was first reported in a case series from 
Denver in 1967.7 The American European 
Consensus Conference (AECC) 1994 defined 
ARDS as ‘an acute inflammatory syndrome mani-
festing as diffuse pulmonary oedema and respira-
tory failure that cannot be explained by, but may 
co-exist with, left-sided heart failure’.8 In 2012, the 
AECC definition was re-evaluated and minor 
alterations were proposed by the European 
Society of Intensive Care Medicine ARDS Defi-
nition Task Force. This iteration recognised 3 
grades of severity depending on the degree 
of hypoxaemia and stipulated the application 
of at least 5 cmH2O of positive end-expira-
tory pressure (PEEP) or continuous positive 
airway pressure. This so-called Berlin defini-
tion was validated using retrospective cohorts 
and captures patients with a mortality of 24% 
in patients with mild ARDS, rising to 48% in 
2 Griffiths MJD, et al. BMJ Open Resp Res 2019;6:e000420. doi:10.1136/bmjresp-2019-000420
Open access
the group of patients with the most severe respiratory 
failure.9
A four-point lung injury scoring system (Murray Score 
or LIS) is the most widely used means of quantifying 
ARDS severity. It is based on the level of PEEP, the ratio 
of the partial pressure of arterial oxygen (PaO2) to the 
fraction of inspired oxygen (FiO2), the dynamic lung 
compliance and the degree of radiographic infiltration.7 
Although the LIS has been widely used in clinical studies 
and a score of >3.0 is commonly used as a qualifying 
threshold for support with extracorporeal membrane 
oxygenation (ECMO), it cannot predict outcome during 
the first 24–72 hours of ARDS.8 When the scoring system 
is used 4–7 days after the onset of the syndrome, scores of 
2.5 or higher predicted a complicated course requiring 
prolonged mechanical ventilation.9
As a syndrome rather than a disease, there is no labo-
ratory, imaging or other ‘gold standard’ diagnostic inves-
tigation for ARDS. Therefore like acute kidney injury 
(AKI), ARDS is caused by a huge range of conditions and 
as a consequence patients with ARDS are heterogeneous. 
The outcome of these patients is determined by the 
underlying causes of ARDS, patient-specific factors such 
as comorbidities, clinical management and the severity 
of illness.
Epidemiology and outcomes
Using the AECC definition, several population-based 
studies of ARDS showed a fairly consistent picture of 
the age, mortality and severity of illness; however, there 
was almost a fourfold difference in incidence, probably 
contributed to by differences in study design and ICU 
utilisation.10 In the USA, there are estimated to be 190 000 
cases and 74 000 deaths annually from ARDS.11 Whereas 
in a third world setting, from 1046 patients admitted to a 
Rwandan hospital over 6 weeks, 4% (median age 37 years) 
met modified ARDS criteria. Only 30.9% of patients with 
ARDS were admitted to an ICU, and hospital mortality 
was 50.0%. This study used the Kigali modification of 
the Berlin definition: without a requirement for PEEP, 
hypoxia threshold of SpO2/FiO2 less than or equal to 
315, and bilateral opacities on lung ultrasound or chest 
radiograph.12
The recently published LUNG SAFE trial was designed 
to study prospectively the performance of the Berlin defi-
nition and to reflect modern management of ARDS. To 
those ends, the investigators recorded admissions over 
4 weeks to 459 ICUs in 50 countries over 5 continents 
including 29 144 patients. In total, 3022 (10.4%) cases 
fulfilled ARDS criteria, including almost a quarter of 
those supported with invasive mechanical ventilation.13 
Despite this relatively high prevalence and the study’s 
focus on ARDS, the syndrome was recognised in only 
half of the mild ARDS group. Furthermore, in a study 
that reported on 815 patients with at least one risk factor 
for ARDS who were admitted to one of 3 Spanish hospi-
tals over 4 months, 15 out of 53 patients (28%) were not 
admitted to an ICU suggesting that LUNG SAFE may 
have underestimated both ARDS incidence and over-
looked diagnoses.14
Survivors commonly suffer from muscle weakness and 
neuropsychiatric problems, such that fewer than 50% 
have returned to work 12 months after leaving intensive 
care.15 However, it is unusual for ARDS survivors to be 
significantly limited by chronic respiratory failure. There-
fore, ARDS is important both clinically and financially, 
because it is a not uncommon contributor to the deaths 
of critically ill patients of all ages and because survivors 
carry on suffering from the sequelae of critical illness 
long after they leave hospital.16
Pathophysiology
The pathophysiology of ARDS results from acute inflam-
mation affecting the lung’s gas exchange surface, the 
alveolar-capillary membrane.1 Increased permeability of 
the membrane associated with the recruitment of neutro-
phils and other mediators of acute inflammation into 
the airspace manifests as high permeability pulmonary 
oedema. The resulting acute inflammatory exudate inac-
tivates surfactant leading to collapse and consolidation 
of distal airspaces with progressive loss of the lung’s gas 
exchange surface area. This would be compensated for 
by hypoxic pulmonary vasoconstriction, if the inflamma-
tory process did not also effectively paralyse the lung’s 
means of controlling vascular tone, thereby allowing 
deoxygenated blood to cross unventilated lung units on 
its way to the left heart. The combination of these two 
processes causes profound hypoxaemia and eventually 
type 2 respiratory failure as hyperventilation fails to keep 
pace with carbon dioxide production.
diagnosis
Any diagnostic strategy for ARDS is sufficiently dependent 
on local factors, such as the prevalent causes of infec-
tious pneumonia and access to imaging modalities, that 
a single protocol cannot be recommended. An exem-
plar from a tertiary referral centre used to dealing with 
complex and very severe cases is included (figure 1, p43–
44). There are two main broad categories of condition 
that resemble ARDS but have a distinct pathophysiology: 
first, cardiovascular conditions of rapid onset including 
left heart failure, right-to-left vascular shunts usually with 
some lung pathology and major pulmonary embolism; 
second, lung conditions which develop more slowly than 
ARDS, for example, interstitial lung diseases (especially 
acute interstitial pneumonia), bronchoalveolar cell carci-
noma, lymphangitis and the pulmonary vasculitides.
tEchnIcAl summAry
The guidelines for the management of adult patients 
with ARDS were created by a multidisciplinary writing 
group constituted by the Joint Standards Committee of 
the Faculty of Intensive Care Medicine and the ICS. All 
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Figure 1 Sixty-day and hospital mortality comparing LTV and HTV mechanical ventilation in adult patients with ARDS. 
ARDS, acute respiratory distress syndrome; HTV, higher tidal volume; LTV, lower tidal volume.
group members, including lay members, are coauthors of 
the guideline. The group first met in 2013 and completed 
the guidelines in 2018. The guidelines have undergone 
both independent external peer review and input from 
stakeholder organisations.
The process for guideline creation adhered to that of 
the National Institute for Health and Care Excellence 
(NICE). In brief, the writing group first performed a 
scoping exercise on the topic, having decided that the 
focus should be on effective treatment interventions. Ten 
topics were chosen based on existing guideline recom-
mendations and the experience of committee members. 
These included:
 ► Corticosteroids.
 ► ECMO.
 ► ECCO2R.
 ► Fluid strategy.
 ► High-frequency oscillation ventilation (HFOV).
 ► Inhaled vasodilators (iVasoD).
 ► Lung protective ventilation: tidal volume (Vt).
 ► Neuromuscular blocking agents (NMBA).
 ► PEEP.
 ► Prone positioning.
Each topic was developed into a full protocol using the 
PICO (Population, Intervention, Comparison, Outcome) 
formulation. Search strategies for each topic were then 
developed by the group information expert with a focus 
on systematic reviews (SR) and meta-analyses (MA). Each 
topic was assigned to two group members with one acting 
as topic lead. High-quality MA and SR were selected and 
the references placed in an Endnote database. Prese-
lected outcome data were extracted from these reviews, 
using the most up-to-date MA where possible. Data from 
older MA were used if not all the preselected outcomes 
could be extracted from the most recent MA.
The guidelines used the internationally recognised 
GRADE methodology.17 Group members received 
training on the GRADE process and were given a 
resource pack, which included a practical guide which 
was created in- house. GRADE makes recommendations 
based on patient centred and predetermined outcomes. 
It does not judge the quality of individual randomised 
controlled trials (RCTs) but makes quality assessments on 
the predetermined outcomes, which, where possible, are 
extracted from published MA.18
The following outcomes were chosen by the writing 
group as either of critical or high importance using the 
GRADE methodology:
Mortality (28 day, hospital and 6 month): Critically 
important.
Mortality (1 year): Critically important.
Length of stay (ICU and hospital): Important.
Quality of life (at 3 months): Critically important.
Quality of life (at 6 months and 1 year): Important.
Harms (at 3 months, 6 months and 1 year): Important.
GRADE has a transparent methodology and guides 
recommendations based on the evidence collected. 
In reality, treatment recommendations are a gradua-
tion. However, in order to aid clinical decision-making, 
GRADE converts the continuum into five mutually exclu-
sive categories.17 Recommendations are therefore catego-
rised as strongly in favour, weakly in favour (or conditional), 
strongly against or weakly against (conditional). Finally, a 
research recommendation can be made where the estimate 
of the magnitude of effect and its boundaries were so 
imprecise and wide that further research is likely to make 
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Table 1 Corticosteroids compared to placebo for ARDS
Patient or population: adults with ARDS
Settings: intensive care 
Intervention: corticosteroids
Comparison: placebo
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect (95% 
CI)
No. of 
participants 
(studies)
Quality of 
evidence 
(GRADE) Comments
Control risk Intervention risk
Placebo Corticosteroids
Mortality 
(hospital)
526 per 1000 326 per 1000
(121 to 663)
RR 0.62
(0.23 to 
1.26)
561
(five studies)
+---
VERY LOW
Due to serious risk 
of bias, serious 
inconsistency 
and serious 
imprecision
All studies conducted in 
the prelung protection 
strategy era. One study 
changed ventilation 
protocol during the 
study, following ARDS 
Net ARMA result
Mortality 
(hospital or 60 
day)
500 per 1000 455 per 1000
(355 to 590)
RR 0.91
(0.71 to 
1.18)
725
(eight studies)
++--
LOW
Due to serious 
inconsistency 
and serious 
imprecision
Pooled estimate 
from studies of 
both treatment and 
preventative steroids
Adverse 
events
350 per 1000 287 per 1000
(175 to 477)
RR 0.82
(0.5 to 1.36)
494
(four studies)
++--
LOW
Due to serious 
risk of bias 
and serious 
imprecision
Composite of infection; 
neuromyopathy; 
diabetes, 
gastrointestinal bleeding 
and others
Adverse 
event: post-
ICU cognitive 
function
Mean—74.31 Mean—10.71 higher
(5.22 higher to
16.2 higher)
100
(one study)
+---
VERY LOW
Due to very 
serious risk of 
bias and serious 
indirectness
Assessed with: cognitive 
function component of 
QLQ-C30
Scale from: 0 to 100, 
with a higher score 
representing better 
cognitive function
ARDS, acute respiratory distress syndrome; ICU, intensive care unit.
a fundamental change to a recommendation. Recom-
mendations were made by the whole writing group. The 
lead author would present the data and suggest a recom-
mendation, using GRADE methodology, based on the 
balance of benefits and harms as detailed in the GRADE 
tables and evidence. The group would then debate the 
topic and reach a consensus, based on the opinion of the 
majority.
cortIcostEroIds
PIco question
In adults with ARDS, does the use of corticosteroids, 
compared with standard care, affect survival and selected 
outcomes?
study identification
The search strategy was predefined as per the online 
appendix C (https://www. ficm. ac. uk/ sites/ default/ 
files/ appendix_ c_-_ search_ strategies. pdf). The role of 
corticosteroids in ARDS has been studied in RCT both in 
populations at risk of developing ARDS and in the estab-
lished syndrome. These prevention and treatment trials 
have been separately analysed in most SR with MA; the 
results of the former have been excluded from this anal-
ysis. Eight, high quality SRs with MA, performed between 
2008 and 2014, were identified (see PRISMA chart in 
online appendix A (https://www. ficm. ac. uk/ sites/ 
default/ files/ appendix_ a_-_ prisma_ diagrams. pdf).19–26 
A total of eight RCTs performed between 1985 and 2007 
were included in these reviews. The largest single study 
enrolled only 180 patients.
A GRADE Summary of Findings table is shown below 
based on critical and important outcomes (table 1). A 
full GRADE evidence table can be found as part of the 
online appendix B (https://www. ficm. ac. uk/ sites/ 
default/ files/ appendix_ b_-_ grade_ evidence_ tables. pdf).
Analysis of outcomes
Mortality
A MA of hospital mortality alone was presented in two 
SRs,19 21 while combined data on both hospital and 60-day 
mortality were presented in another SR.20 The quality of 
evidence supporting the relative risk (RR) of 0.51 (95% 
CI 0.24 to 1.09) in hospital mortality with steroids was 
very low21 (see GRADE evidence profile table 1). There 
was a serious risk of bias with only 75% of the Cochrane 
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risk of bias recommendations followed. Inconsistency 
was also serious with point estimates varying widely, confi-
dence intervals overlapping, a lack of consistent direc-
tion of effect and significant heterogeneity (I2 52%). 
Imprecision was also serious. A posthoc power calcula-
tion suggests that the pooled studies only had an approx-
imately 65% power and a sample size calculation based 
on the reported effect size suggested that sample size was 
inadequate (predicted sample size of 474; actual pooled 
sample size of 341 for hospital mortality). This is likely 
to be an underestimate of the sample size required, as 
the effect size is likely to be smaller than the pooled data 
suggest due to heterogeneity of the studies.
A further issue is the fact that the majority of these 
studies were performed in the prelung protection 
strategy era. The largest ARDS Network steroid study, 
LASARUS, changed its ventilation protocol during the 
study to reflect the results of the ARDS Network ARMA 
low tidal volume study.27
The other hospital mortality analysis also reported 
low-quality data with an estimated RR of 0.62 (0.23–
1.26).19 Combining hospital and 60-day mortality gave 
a RR estimate of 0.91 (0.71–1.18) with serious inconsis-
tency and indirectness issues including the fact that this 
was a pooled estimate of both preventative and treatment 
studies.20
Length of stay
A MA of hospital length of stay was presented in one SR 
and MA.22 A mean reduction of 4.8 days with steroid treat-
ment was reported but the overall quality of the studies 
was very low.
Quality of life
This was not reported in the Included MA.
Economic data
No economic data were published in the trials included.
Treatment harms
Potential harms of treatment with steroids included 
excess hospital acquired infections, ICU acquired weak-
ness and delirium. The only available MA reported a 
composite analysis of infection, ICU acquired weakness, 
diabetes, gastrointestinal bleeding and other compli-
cations.21 The RR reported was 0.82 (0.5–1.36) but the 
quality of the trials was low.
GrAdE recommendation statement
The use of corticosteroids in established ARDS should 
be the subject of a suitably powered, multicentre RCT 
with long-term follow-up (GRADE Recommendation: 
research recommendation).
GrAdE recommendation justification
Current evidence includes the possibility of substan-
tial patient benefit and the risk of harm appears small, 
although the group noted that the trials did not include 
longer term follow-up of survivors. However, the evidence 
is of low to very low quality from clinical trials, which were 
mostly conducted before the current era of lung protec-
tive ventilation. In addition, the lack of sufficient power 
in any individual study or in the combined MA and the 
heterogeneity of the dose, timing and agent used also 
influenced the decision. The group believed that a posi-
tion of equipoise exists and the research recommenda-
tion reflects this view.
As a caveat, it is worth mentioning that specific steroid 
responsive disorders may mimic ARDS, for example, 
pneumocystis jiroveci pneumonia, acute eosinophilic 
pneumonia and diffuse alveolar haemorrhage.
Implications for future research
A large, multicentre study on steroids in established 
ARDS is currently planned.
ExtrAcorPorEAl mEmbrAnE oxyGEnAtIon
PIco question
In adults with ARDS, does the use of ECMO, compared 
with standard care affect survival and selected outcomes?
study identification
The search strategy was predefined as per online appendix 
C. Eight, relevant SR were identified, of which three 
included a MA28–30 (see PRISMA chart in online appendix 
A). When analysing results, we used the most recent SR 
with MA that considered the outcome in question.29 The 
selected SR with MA included only two RCTs of ECMO 
in adults with ARDS. These RCTs were published in 1979 
and 2006 and included a total of 270 participants.31 32 
The older RCTs32 did not combine the use of ECMO with 
protective low tidal volume mechanical ventilation and 
so is of little relevance to current practice. Data from this 
RCT and RCTs investigating the use of extracorporeal 
carbon dioxide removal (ECCO2R)
33 34 were excluded. By 
contrast, we included in our de novo MA two quasi-RCT, 
which used genetic matching with replacement to iden-
tify control subjects and compared these with patients 
supported with ECMO in a total of 346 patients, all with 
pandemic H1N1 2009 influenza A.35 36
A GRADE Summary of Findings table is shown based 
on critical and important outcomes (table 2). A full 
GRADE evidence table can be found as part of the online 
appendix B.
Analysis of outcomes
Mortality
Hospital mortality was studied in two quasi-RCT in patients 
with H1N135 36 and hospital mortality was combined with 
mortality up to 6 months after hospital discharge in the 
RCT (CESAR) that recruited a general adult population 
with severe ARDS.31 Point estimates consistently showed a 
reduction in mortality in patients supported with ECMO: 
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Table 2 ECMO compared to standard care for ARDS
Patient or population: adults with ARDS
Settings: intensive care
Intervention: ECMO
Comparison: standard care
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect (95% 
CI)
No. of 
participants 
(studies)
Quality of evidence 
(GRADE) Comments
Control risk Intervention risk
Usual care ECMO
Mortality 
(pooled)
517 per 1000 324 per 1000
(264 to 408)
RR 0.64
(0.51 to 0.79)
505
(three studies)
+---
VERY LOW
Due to serious risk 
of bias and serious 
indirectness
Includes data from 
two quasirandomised 
trials of patients with 
influenza A H1N1
Adverse event: 
bleeding
0 per 1000 250 per 1000 RR 26.02
(3.68 to
184.16)
249
(two studies)
+---
VERY LOW
Due to serious risk 
of bias and serious 
indirectness
ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation.
the risk ratio for hospital mortality was 0.64 (0.51–0.79). 
However, owing to the potential bias and lack of gener-
alisability in the quasi-RCTs, the quality of evidence was 
deemed to be very low.
Length of stay
This was not reported in the included MA.
Quality of life
This was not reported in the included MA.
Economic data
This was not reported in the included MA. The CESAR 
study alone included both cost utility and cost effective-
ness analyses enabling investigators to predict a lifetime 
cost per quality-adjusted life year (QALY) for ECMO of 
£19 252 (CI 7622 to 59 200) at a discount rate of 3.5%.31
Treatment harms
The use of ECMO is associated with the risk of serious 
bleeding, although this has not been universally reported 
or consistently defined in published studies. The risk 
ratio for bleeding associated with ECMO was 11.44 
(3.11–42.06). The quality of evidence was deemed to be 
very low because data were available from two non-ran-
domised studies that only included patients with ARDS 
associated with influenza A (H1N1).35 36
Grade recommendation statement
We do not recommend the routine use of ECMO for all 
patients with ARDS (GRADE Recommendation: weakly 
against). We suggest the use of ECMO with lung-pro-
tective mechanical ventilation in selected patients with 
severe ARDS (GRADE Recommendation: weakly in 
favour).
Grade recommendation justification
The use of ECMO in selected adults suffering severe 
ARDS (defined as a Lung Injury Score of 3 or more or 
pH<7.20 due to uncompensated hypercapnoea),was 
given a weakly positive recommendation based on very 
low quality evidence. The most widely used indications 
for ECMO are those reported in the CESAR study.31 
There is a paucity of data to make this judgement: one 
RCT remains after excluding studies including patients 
supported with ECCO2R and one RCT from 1979 in 
which mechanical ventilation was not protective. Argu-
ably the predominant mechanism through which ECMO 
may confer a benefit is by enabling the dramatic reduc-
tion of ventilation volumes and pressures, thereby miti-
gating ventilator-associated lung injury (VALI).
Scant evidence, again of very low quality, suggested 
an increased risk of bleeding associated with the use of 
ECMO: consistent with data from the extracorporeal life 
support organisation (ELSO), which publishes its registry 
data from around 300 centres world-wide. The incidence 
of serious bleeding (approximately 15% overall) and 
intracranial haemorrhage (3.9%) associated with the 
use of veno-venous ECMO for respiratory failure in adult 
patients based on data from the ELSO registry from its 
inception in 1989 to 2016 has recently been reported.37
ExtrAcorPorEAl cArbon dIoxIdE rEmovAl
PIco question
In adults with ARDS, does the use of ECCO2R, compared 
with standard care affect survival and selected outcomes?
study identification
The role of ECCO2R in ARDS has been studied in two RCTs 
in patients with ARDS enrolling 119 subjects. These trials 
have been analysed in SR without MA: there were signifi-
cant difference between the studies in both ECCO2R tech-
nique and conventional ventilator strategy. Consequently, 
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Table 3 ECCO2R compared to standard care for acute respiratory distress syndrome
Patient or population: adults with ARDS
Settings: intensive care
Intervention: ECCO2R
Comparison: standard care
Outcomes
Relative effect 
(95% CI) No. of participants (studies) Quality of evidence (GRADE) Comments
Mortality 
(hospital)
No MA conducted 457
(13 studies)
+---
VERY LOW
Due to serious risk of bias, 
serious inconsistency, serious 
indirectness and serious 
imprecision
Mostly observational studies. Only two RCTs 
performed. No MA performed as variable 
approach to ECCO2R and standard ventilator 
strategies. Mortality estimates presented as 
simple descriptions
27%–75% (mean 55.5%, SD 47.2 to 60.3)
Adverse events No MA conducted 485
(13 studies)
+---
VERY LOW
Due to serious risk of bias, 
serious inconsistency, serious 
indirectness and serious 
imprecision
0%–25% incidence of arterial injury. Higher 
incidence of transfusion reported in two 
studies.
Complications presented as aggregated 
simple descriptions—0%–25%
ECCO2R, extracorporeal carbon dioxide removal.
the SR was not able to perform a meaningful MA. There 
were two RCTs performed between 1994 and 2013.33 38
A GRADE Summary of Findings table is shown based on 
critical and important outcomes (table 3). A full GRADE 
evidence table can be found as part of the online appendix 
B.
Analysis of outcomes
Mortality
The risk of bias in the two RCTs was low. Both studies were 
stopped early following planned interim analyses and 
concluded that any difference between control and inter-
vention groups was too small to be demonstrated. One 
trial enrolled 79 out of a planned 12033 and the other 40 
out of a planned 60.38 In one RCT, in-hospital mortality 
was 17.5% and 15.4% in the intervention and control 
groups, respectively.33 The other RCT reported 30-day 
mortality in the intervention group of 66.6% and 57.9% 
in the control.38 These were not significantly different.
Length of stay
This was not reported in the included SR.
Quality of life
No trial reported on quality of life.
Economic data
No trial reported on economic data.
Treatment harms
Potential harms of treatment with ECCO2R included 
bleeding and thrombosis. Complications were dependent 
on the type of ECCO2R used with approaches which 
required arterial cannulation reporting an incidence 
of arterial injury from 0% to 25%.39 Blood transfusion 
requirements were also increased in the ECCO2R group.
39
Grade recommendation statement
The use of ECCO2R in established ARDS should be the 
subject of a suitably powered multicentre RCT with long 
term follow-up and economic analysis (GRADE Recom-
mendation: research recommendation).
Grade recommendation justification
Current evidence is extremely limited and mainly consists 
of non-randomised prospective and retrospective trials.40–44 
The substantial differences between the techniques for 
both ECCO2R and conventional ventilation make the 
two RCTs incomparable. However, there is evidence that 
ECCO2R can allow ventilation with tidal volumes lower 
than currently recommended for ARDS and the potential 
benefits of this approach should be tested in an appropri-
ately designed RCT. The group believed that a position of 
equipoise exists and the research recommendation reflects 
this view.
Implications for future research
A large, multicentre study evaluating veno-venous ECCO2R 
to facilitate lower tidal volume ventilation in patients with 
acute hypoxaemic respiratory failure is currently ongoing, 
the REST (protective ventilation with veno-venous lung 
assist in respiratory failure) trial (http://www. nictu. hscni. 
net/ rest- trial). NICE guidelines on the use of ECCO2R 
encourage clinicians to recruit patients to the REST trial.
FluId mAnAGEmEnt
PIco question
In adults with ARDS, does the use of a conservative fluid 
strategy, compared with a liberal fluid strategy or standard 
care, affect survival or selected outcomes?
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Table 4 Conservative compared to liberal fluid management for ARDS
Patient or population: adults with ARDS
Settings: intensive care
Intervention: conservative fluid strategy
Comparison: liberal fluid strategy
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect (95% 
CI)
No. of 
participants 
(studies)
Quality of 
evidence 
(GRADE) Comments
Control risk Intervention risk
Liberal fluid 
strategy
Conservative fluid 
strategy
Mortality (pooled 
up to 60 days)
311 per 1000 283 per 1000
(239 to 332)
RR 0.91
(0.77 to 
1.07)
1206
(five RCTs)
++--
LOW
Due to serious 
indirectness and 
serious imprecision
Variable fluid strategies, 
fluid balance achieved 
and outcome reporting
Adverse event: 
AKI
1000
(one study)
+++- MODERATE
Due to serious 
imprecision
Single study. There 
were a similar number 
of renal failure free days 
between conservative 
and liberal fluid 
management groups. 
In a posthoc analysis 
where creatinine was 
adjusted for fluid 
balance, conservative 
fluid management was 
associated with lower 
incidence of AKI (58% 
vs 66%).
Adverse event: 
RRT
141 per 1000 100 per 1000
(70 to 139)
RR 0.71
(0.50 to 
0.99)
1000
(one study)
+++- MODERATE
Due to serious 
imprecision
Single study
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; RRT, renal replacement therapy.
study identification
The search strategy was predefined as per the online 
appendix C. Of four SR identified,45–48 one recent high 
quality SR with MA addressing the question of optimal 
fluid strategy in ARDS was included.45 This review 
included patients with ARDS, sepsis and SIRS, although 
subgroup data were available for ARDS. The review 
included data from five RCTs in ARDS49–53 performed 
between 2002 and 2014, and ranging from 29 to 1000 
participants. Significant clinical heterogeneity was evident 
between these studies in terms of intervention strategies, 
fluid balance achieved and outcome reporting. Conserv-
ative fluid strategies included protocolised diuretic use, 
with49 50 or without51 hyperoncotic albumin solutions, 
minimisation of fluid intake51 and the use of extravas-
cular lung water (EVLW) measurements to guide fluid 
therapy.52 Liberal fluid strategies varied from a protocol-
ised fluid administration strategy, which approximated 
the usual care arm of previous large trials in ARDS,51 use 
of furosemide without hyperoncotic albumin50 and use 
of pulmonary capillary wedge pressure (PCWP) to guide 
fluid administration.52 One study did not define conserv-
ative and liberal fluid strategies in detail.53
A GRADE summary of findings table is shown for crit-
ical and important outcomes (table 4). A full GRADE 
evidence table can be found as part of the online 
appendix B.
Analysis of outcomes
Mortality
Heterogeneity in outcome reporting was evident, with 
two studies reporting mortality at 30 days49 50 and three at 
60 days;51–53 the pooled results showed no effect of fluid 
balance strategy on mortality.
Moderate quality evidence supported an RR of 0.91 
(95% CI 0.77 to 1.08) for mortality using a conservative 
rather than a liberal fluid strategy. Although two of the 
RCTs included were at high or uncertain risk of bias,52 53 
these studies included only 129 of 1206 patients, and thus 
overall no serious risk of bias was deemed to be present. 
Serious indirectness was present, in that various treat-
ment regimens were compared, including a comparison 
of hyperoncotic albumin versus placebo as an adjunct 
to diuretic therapy,50 and of EVLW-guided with PCWP-
guided fluid therapy.53 Exclusion of these studies made 
little difference to the point estimate. As confidence 
intervals around the point estimate were wide, neither 
clinically important benefit nor harm could be excluded.
Length of ICU stay
Very low quality evidence for a reduction in length of 
ICU stay with a conservative fluid strategy was provided by 
two small RCTs including 129 patients.52 53 Both studies 
were at very serious risk of bias due to lack of blinding 
and other methodological flaws. One study52 compared 
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EVLW-guided with PCWP-guided fluid therapy, neither 
of which is commonly used clinically, and a clinically 
important difference in fluid balance between groups 
was absent. The population, intervention and compar-
ator in the other study were not reported in detail.53 The 
small number of patients in these studies also led to very 
serious imprecision.
Length of hospital stay
A single RCT50 provided low-quality evidence for the 
absence of an effect of fluid strategy on length of hospital 
stay. Very serious imprecision was present due to a lack of 
statistical power to exclude a clinically important differ-
ence on this outcome.
Quality of life
No trial reported on quality of life.
Economic data
No trial reported on economic data.
Treatment harms
Acute kidney injury incidence
Incidence of acute kidney injury (AKI) was felt to be 
important as this represents a potential harm associated 
with a conservative fluid strategy. A single large RCT51 
provided low quality evidence for similar numbers of 
AKI-free days with conservative and liberal fluid strate-
gies, and a posthoc analysis of this trial54 suggested a 
reduction in AKI incidence with a conservative fluid 
strategy using creatinine measurements corrected for 
changes in volume of distribution.
Requirement for renal replacement therapy
It was considered that requirement for renal replace-
ment therapy (RRT) represented a potential harm from a 
conservative fluid strategy. Moderate quality evidence for 
a reduction in the requirement for RRT with a conserv-
ative fluid strategy was provided by a single large RCT51 
(RR 0.71, 95% CI 0.50 to 0.99).
Cognitive dysfunction
A posthoc analysis of a small subgroup of patients from 
the FACTT trial found conservative fluid strategy to be an 
independent risk factor for long-term cognitive dysfunc-
tion following ARDS.55 One RCT of uncertain risk of bias 
found better cognitive outcome scores with conservative 
fluid strategy than with liberal fluid strategy,53 although 
the duration of follow-up and details of the intervention 
were not described.
Grade recommendation statement
We suggest the use of a conservative fluid strategy in 
patients with ARDS (GRADE recommendation: weakly in 
favour).
Grade recommendation justification
Despite the low quality of evidence for the majority of 
outcomes, and the results being driven largely by a single 
trial,51 conservative fluid management may be beneficial 
without evidence of harm. We therefore suggest that in 
adult patients with ARDS, clinicians consider the use of 
a conservative fluid strategy which uses fluid restriction, 
diuretics and possibly hyperoncotic albumin to avoid 
a positive fluid balance in preference to a liberal fluid 
strategy.
vEntIlAtIon hIGh FrEquEncy oscIllAtory
PIco question
In adults with ARDS, does the use of HFOV, compared 
with standard care, affect survival and other selected 
outcomes?
study identification
The search strategy was predefined as per online 
appendix C. The role of HFOV in ARDS with moderate 
to severe hypoxaemia has been studied in six RCTs 
published between 2002 and 2013.56–61 Two recent RCTs 
enrolled a disproportionate number of patients—1343 
out of 1608 patients (795 patients in one and 548 in 
the other). There have been an additional two RCTs of 
HFOV combined with tracheal gas insufflation.62 63 These 
trials have been analysed in three SRs with MA.64–66
Data were analysed from two of these: the most recent 
MA was used first,64 supplemented with additional data 
from previous studies.65 One MA was excluded as it 
combined results of RCTs with HFOV and tracheal gas 
insufflation with those of RCTs with HFOV alone.66
A GRADE Summary of Findings table is shown below 
based on critical and important outcomes (table 5). A 
full GRADE evidence table can be found as part of online 
appendix B.
Analysis of outcomes
Mortality
The RR of death associated with HFOV was 1.218 (0.925 
to 1.604). The evidence was judged to be of moderate 
quality.64 Of the RCTs contributing to the two MAs, 
five demonstrated no difference in mortality between 
HFOV and conventional ventilation,56–61 while one of 
the larger RCTs demonstrated increased mortality in 
the HFOV arm.59 The overall risk of bias in included 
studies was low with the exception of two studies where 
crossovers accounted for more than 10% of the study 
group.56 58 Inconsistency was serious with point estimates 
varying widely, confidence intervals overlapping, a lack 
of consistent direction of effect and significant heteroge-
neity (I2=63.1%, p=0.028).
Length of stay
This was not reported in the included SR.
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Quality of life
No trial reported on quality of life.
Economic data
No trial reported on economic data.
Treatment harms
Potential harms of HFOV were reported including baro-
trauma, hypotension and oxygenation failure. The RR of 
barotrauma was reported from four studies enrolling 752 
subjects as 1.205 (95% CI 0.834 to 1.742); however, the 
studies used a variable definition of barotrauma.64 The 
RR of hypotension was reported as 1.326 (95% CI 0.271 
to 6.476) and these data were derived from three studies 
enrolling 237 patients.64 Oxygenation failure in the MA 
included 757 patients from three studies with a RR for 
HFOV of 0.557 (95% CI 0.351 to 0.884).64
Grade recommendation statement
We do not recommend the use of HFOV in the manage-
ment of patients with ARDS (GRADE recommendation: 
strongly against).
Grade recommendation justification
The use of HFOV for the management of ARDS was given 
a GRADE recommendation of strongly against based 
on moderate quality evidence. Current evidence from 
multiple RCTs demonstrated no benefit from HFOV and 
one RCT demonstrated an increase in mortality with 
HFOV.
InhAlEd vAsodIlAtors
PIco question
In adults with ARDS, does the use of inhaled vasodi-
lators (iVasoD), compared with standard care, affect 
survival and selected outcomes?
study identification
The search strategy was predefined as per online 
appendix C. The role of the iVasoD nitric oxide (iNO) in 
the management of ARDS has been assessed in multiple 
RCT, which have been analysed in subsequent SR with 
MA. No studies examining the role of nebulised prosta-
cyclin in adults with ARDS were identified by Cochrane 
reviewers in 2010.67
Three SR with MA were identified from which data 
were analysed (see PRISMA chart in online appendix 
A).68–70 Mortality data were analysed from nine RCTs71–79 
published between 1998 and 2004, including 1142 partic-
ipants. Exclusion criteria for RCT included: >50% cross-
over between iNO and placebo groups and unequal 
distribution of other rescue therapies between treatment 
and control groups. Limited information on possible 
harms was available: data from four RCTs71 73 77 78 provided 
specific information regarding nephrotoxicity associated 
with the use of iNO.
Table 5 HFOV compared to usual care for ARDS
Patient or population: adults with ARDS
Settings: intensive care
Intervention: HFOV
Comparison: standard care
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect (95% 
CI)
No. of 
participants 
(studies)
Quality of 
evidence 
(GRADE) Comments
Control risk Intervention risk
Standard care HFOV
Mortality (ICU) 308 per 1000 442 per 1000
(308 to 447)
RR 1.22
(0.93 to 1.60)
1321
(three studies)
+++-
MODERATE
Due to moderate 
inconsistency and 
mild indirectness
Changes in 
conventional 
ventilation 
strategies 
accounted for 
heterogeneity
Mortality (30 
day)
436 per 1000 453 per 1000
(362 to 571)
RR 1.04
(0.83 to 1.31)
1580
(five studies)
+++-
MODERATE
Due to moderate 
inconsistency and 
mild indirectness
Changes in 
conventional 
ventilation 
strategies 
accounted for 
heterogeneity
Adverse events: 
barotrauma
122 per 1000 147 per 1000
(101 to 212)
RR 1.205
(0.834 to
1.742)
752
(four studies)
++--
LOW
Due to serious 
imprecision
Barotrauma 
variably defined
Adverse events: 
oxygen failure
102 per 1000 77 per 1000
(61 to 89)
RR 0.557
(0.351 to
0.884)
757
(three studies)
++--
LOW
Due to serious 
imprecision
Oxygenation failure 
variably defined.
ARDS, acute respiratory distress syndrome; HFOV, high-frequency oscillatory ventilation.
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A GRADE Summary of Findings table is shown below 
based on critical and important outcomes (table 6). A 
full GRADE evidence table can be found as part of online 
appendix B.
Analysis of outcomes
Mortality
Mortality at hospital discharge was used for analysis 
where available. Otherwise these data were combined 
with mortality at discharge from the ICU or 28–30 days 
after randomisation. The quality of evidence supporting 
the RR of 1.10 (95% CI 0.94 to 1.29: p=0.24) in the 
first treatment analysis was low (see GRADE evidence 
profile table). In only 3/9 studies72 78 79 was placebo gas 
(nitrogen) administered to the control group, creating 
a serious risk of bias in the other six studies. There was 
serious indirectness in the nine studies analysed owing to 
variability in inclusion criteria including marked devia-
tion from AECC criteria for diagnosing ALI/ARDS and 
variable iNO treatment regimens. Data from studies using 
different doses of iNO were combined. These variable 
doses and duration of treatment, which may be consid-
ered to be too high and too long respectively, constitute a 
serious source of indirectness. Consistency was good with 
confidence intervals overlapping, a consistent direction 
of effect and a very low heterogeneity.70
Subgroup analysis from 7/9 trials did not support 
the hypothesis that iNO conferred a survival benefit in 
patients with severe ARDS (PaO2 to FiO2 ratio of <20 
kPa).
Length of stay
No MA available.
Quality of life
No trial reported on quality of life.
Economic data
No trial reported on economic data.
Treatment harms
The administration of iNO was associated with an 
increased incidence of renal dysfunction in four trials 
representing 80% of the patients recruited into the nine 
studies analysed above (risk ratio 1.50, 1.11 to 2.02). The 
quality of the evidence supporting the association was 
judged to be low based on the factors outlined above and 
the variable criteria used to define renal dysfunction, 
although the consistency between trials was good.
Grade recommendation statement
We do not suggest using iNO in patients with ARDS 
(GRADE Recommendation: weakly against).
Grade recommendation justification
The recommendation that iNO is not used for adult 
patients with ARDS is based on low quality but consistent 
evidence suggesting a lack of mortality benefit and an 
association with renal dysfunction. While the studies 
examining the role of iNO in ARDS are imperfect, further 
trials would be given a low priority. The possible use of 
Table 6 iVasoD compared to placebo or usual care for ARDS
Patient or population: adults with ARDS
Settings: intensive care
Intervention: iNO for all studies
Comparison: placebo or usual care
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect 
(95% CI)
No. of 
participants 
(studies)
Quality of 
evidence 
(GRADE) Comments
Control risk Intervention risk
Placebo/Usual 
care iVasoD
Mortality 
(pooled)
315 per 1000 346 per 1000
(296 to 406)
RR 1.10
(0.94 to 
1.29)
1142
(nine studies)
++--
LOW
Due to 
serious risk 
of bias and 
serious 
indirectness
Six out of nine studies 
compared iNO with usual 
care rather than placebo
Highly variable dose 
and duration of iNO and 
inclusion criteria
Adverse 
event: renal 
dysfunction
124 per 1000 191 per 1000
(142 to 258)
RR 1.55
(1.15 to 
2.09)
919
(four studies)
++--
LOW
Due to 
serious risk 
of bias and 
serious 
indirectness
Highly variable dose 
and duration of iNO and 
inclusion criteria
Variable criteria used to 
define renal dysfunction
ARDS, acute respiratory distress syndrome; iNO, iVasoD, inhaled nitric oxide; iVasoD, inhaled vasodilators.
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iNO in patients with severe right ventricular dysfunction 
or extreme hypoxaemia for short periods, while more 
long-term rescue strategies (such as ECMO) are insti-
tuted, fall outside the scope of this guideline.
mEchAnIcAl vEntIlAtIon At lowEr tIdAl volumE
PIco question
In mechanically ventilated adult patients with ARDS, do 
lower tidal volumes compared with higher, conventional 
tidal volumes affect survival and other related outcomes?
study identification
The search strategy was predefined as per online appendix 
C. Seven, full text, SR were assessed for eligibility. We 
excluded four reviews: three did not contain the full 
complement of published trials80–82 and one contained 
studies of patients without ARDS.83 The remaining three 
reviews84–86 each contained the six RCT that met the 
PICO inclusion criteria. We extracted the mortality data 
provided by Petrucci 201385 (the most recent published 
review) to the GRADE profiler. In addition, we reviewed 
the published papers and extracted additional outcomes 
that were relevant to the guidelines, but not reported in 
the three SR.
The Petrucci 2013 review included six multi-centre 
RCT published from 1998 to 2006 that included a total of 
1297 patients. Within-trial sample sizes ranged from 52 to 
861 patients. Trials were conducted in North and South 
America and Europe. Four trials87–90 compared lower 
tidal volumes (range <6–8 mL/kg) and restricted airway 
pressures (plateau pressure<30 cmH2O) with higher 
tidal volumes (range 9–15 mL/kg) and airway pressures 
(plateau pressure <50–60 cmH2O). The Amato 1998 92 
and Villar 2006 93 trials compared lower tidal volume 
with higher PEEP, where possible set just above the lower 
inflection point of a pressure-volume curve, and higher 
tidal volume with lower PEEP: these studies investigating 
the composite intervention of lower tidal volume and 
higher PEEP were analysed separately.
We provide Forest plots to show the separate MA for 
the comparisons of (1) lower versus higher tidal volumes 
with similar PEEP and (b) lower tidal volumes with 
higher PEEP versus higher tidal volume with lower PEEP. 
A GRADE Summary of Findings table is shown based on 
critical and important outcomes (table 7). A full GRADE 
evidence table can be found as part of online appendix 
B.
Analysis of outcomes
Lower versus higher tidal volume with similar PEEP
Mortality
In this comparison, four studies reported mortality at 
varying time-points: 60 days91 and hospital discharge 
(figure 1).87–89 Pooled data from the four trials showed 
no significant difference between lower and higher tidal 
volume groups in risk of death including all time-points 
(RR 0.87, 95% CI 0.75 to 1.01, p=0.07) with moderate, but 
non-significant heterogeneity (I2 48%, p=0.13). Pooled 
data for hospital mortality showed a statistically signifi-
cant reduction in risk of death (RR 0.83, 95% CI 0.71 to 
0.98, p=0.02) associated with lower tidal volume ventila-
tion, whereas a non-significant increase in risk was found 
at 60 days (RR 1.23, 95% CI −0.80 to 1.89, p=0.35) based 
on data from a single study with relatively few patients, 
in which body weight was not corrected according to the 
ideal or predicted standard (http://www. ardsnet. org/ 
files/ pbwtables_ 2005- 02- 02. pdf).
ICU length of stay
The pooled effect from two studies90 91 showed no signif-
icant difference in length of ICU stay (mean difference 
4.79 days, 95% CI −2.06 to 11.63, p=0.17) (figure 2).
Hospital length of stay
There was no difference in hospital length of stay 
reported by one study90 (mean difference 6.30 days, 95% 
CI −7.53 to 20.13, p=0.37).
Quality of life
No trial reported on quality of life.
Economic data
No trial reported on economic data.
lower tidal volume with higher PEEP versus higher, 
conventional tidal volume with lower PEEP
Mortality: 28-day, ICU and hospital
Two studies reported mortality. At 28 days, one study92 
showed a significant reduction in risk of death in the 
lower tidal volume and higher PEEP group (RR 0.54, 
95% CI 0.31 to 0.91, p=0.02). Similarly, pooled data 
from two studies showed a significant reduction in risk 
of ICU mortality (RR 0.57, 95% CI 0.40 to 0.82, p=0.002) 
and hospital mortality (RR 0.62, 95% CI 0.44 to 0.87, 
p=0.006).92 93 In both cases, the evidence was downgraded 
to low because of imprecision (relatively few patients, 
156 in total), and indirectness of evidence (methodolog-
ical flaws—body weight was not corrected in one study; 
and lack of generalisability based on the unusually high 
mortality rate of the conventional ventilation group).
Grade recommendation statement
We recommend the routine use of lower tidal volumes 
for the management of patients with ARDS (GRADE 
Recommendation: strongly in favour).
Grade recommendation justification
The recommendation to use lower tidal volume (less 
than or equal to 6 mL/kg predicted body weight) venti-
lation with a plateau pressure less than or equal to 30 
cmH2O is strong despite moderate quality of evidence 
for hospital mortality and barotrauma, but low quality of 
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evidence for 60-day mortality. The evidence was down-
graded for serious indirectness for hospital mortality, and 
for inconsistency and imprecision for 60 day mortality. 
For example, the beneficial effects of low tidal volume 
ventilation were only seen in one large trial and the 
means of managing respiratory acidosis in the ARDS 
Network ARMA trial87 is not generally applied. However, 
a lack of adverse effects associated with the intervention, 
strong mechanistic rationale for its use94 and supportive 
data from ARDS prevention studies95 have resulted in its 
universal acceptance as a gold standard of care.
nEuromusculAr blockInG AGEnts
PIco question
In adults with ARDS, does the use of NMBA, compared 
with standard care, affect survival and selected outcomes?
Table 7 Lower tidal volume compared with higher tidal volume (at similar PEEP) for ARDS
Patient or population: adults with ARDS
Settings: intensive care
Intervention: lower tidal volume
Comparison: higher, conventional tidal volume
Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality of evidence
(GRADE) Comments
Control risk Intervention risk
Higher tidal 
volume Lower tidal volume
Mortality (60 
day)
379 per 1000 467 per 1000 (303 to 
717)
RR 1.23
(0.8 to 
1.89)
116
(one study)
++--
LOW
Due to inconsistency and imprecision
Mortality 
(hospital)
408 per 1000 338 per 1000
(290 to 400)
RR 0.83
(0.71 to 
0.98)
1033
(three studies)
+++-
MODERATE
Due to serious indirectness
Adverse 
event: 
barotrauma
30 per 1000 35 per 1000
(19 to 65)
RR 1.17
0.63 to 
2.18
1149
(four studies)
+++-
MODERATE
Due to serious indirectness
Lower tidal volume and higher PEEP compared with higher tidal volume and lower PEEP for ARDS
Patient or population: adults with ARDS
Settings: intensive care
Intervention: lower tidal volume and higher PEEP (LV/PEEP)
Comparison: higher tidal volume and lower PEEP (HV/PEEP)
Outcomes
Illustrative comparative risks* 
(95% CI)
Relative effect 
(95% CI)
No. of 
participants 
(studies)
Quality of evidence 
(GRADE) Comments
Control risk Intervention risk
Low PEEP/ 
HIGH TV
High PEEP/ Low 
TV
Mortality (ICU) 594 per 1000 339 per 1000
(238 to 487)
RR 0.57
(0.4 to 0.82)
148
(two studies)
++--
LOW
Due to inconsistency 
and imprecision
ARDS Net ARMA study 
control group had higher 
TVs (11.5/12) than controls 
in the other four studies
Mortality (28 day) 708 per 1000 383 per 1000
(220 to 645)
RR 0.54
(0.31 to 0.91)
53
(one study)
++--
LOW
Due to inconsistency 
and imprecision
Mortality (hospital) 609 per 1000 377 per 1000
(268 to 530)
RR 0.62
(0.44 to 0.87)
148
(two studies)
++--
LOW
Due to inconsistency 
and imprecision
Adverse events: 
nosocomial 
pneumonia
458 per 1000 587 per 1000
(344 to 999)
RR 1.28
(0.75 to 2.18)
53
(one study)
++--
LOW
Due to inconsistency 
and imprecision
Adverse events 214 per 1000 165 per 1000
(105 to 261)
RR 0.77
(0.49 to 1.22)
254
(two studies)
++--
LOW
Due to inconsistency 
and imprecision
ARDS, acute respiratory distress syndrome; ICU, intensive care unit; PEEP, positive end-expiratory pressure.
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study identification
The search strategy was predefined as per online 
appendix C. The only NMBA studied in an RCT consid-
ering outcomes relevant to our PICO question was cisatra-
curium besylate. Four SR were identified,96–99 published 
between 2012 and 2015, of which only two included 
MA.96 97 When analysing results, we used the most recent 
SR with MA96 that considered the outcome in question. 
The two selected SR with MA included the three RCTs 
of NMBAs that were identified, both of which compared 
a continuous 48 hours infusion of cisatracurium with 
standard care. These RCTs were published between 2004 
and 2010 and included a total of 431 participants from 
20 French ICUs.
A GRADE Summary of Findings table is shown based 
on critical and important outcomes (table 8). A full 
GRADE evidence table can be found as part of online 
appendix B.
Analysis of outcomes
Mortality
Mortality (pooled 28 day, ICU and hospital mortality) 
was reported in all three RCTs100–102 with point esti-
mates showing a reduction in mortality at each of these 
time points. However, in each of these RCT, the 95% CI 
for the risk ratio reached or crossed the no effect line. 
When mortality data from these RCTs were pooled in MA 
(with a total of 431 participants), the CI was narrowed 
to show a significant reduction in mortality at each of 
these time points. The risk ratios for 28 day, ICU and 
hospital mortality were 0.66, 0.70 and 0.72, respectively, 
Figure 2 ICU length of stay comparing LTV and HTV mechanical ventilation in adult patients with ARDS. ARDS, acute 
respiratory distress syndrome; HTV, higher tidal volume; ICU, intensive care unit; LTV, lower tidal volume.
Table 8 NMBAs compared to placebo for ARDS
Patient or population: adults with ARDS
Settings: intensive care
Intervention: NMBAs, cisatracurium infusion in all studies
Comparison: placebo
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect 
(95% CI)
No. of 
participants 
(studies)
Quality of 
evidence 
(GRADE) Comments
Control risk Intervention risk
Placebo NMBAs
Mortality (ICU) 447 per 1000 313 per 1000
(246 to 398)
RR 0.70
(0.55 to
0.89)
431
(three studies)
+++- MODERATE
Due to serious risk 
of bias and serious 
indirectness
All trials studied a 
48 hours infusion of 
cisatracurium besylate
Mortality (28 
day)
389 per 1000 257 per 1000
(195 to 339)
RR 0.66
(0.50 to
0.87)
431
(three studies)
+++-
MODERATE
Due to serious risk 
of bias and serious 
indirectness
See above
Mortality 
(hospital)
471 per 1000 339 per 1000
(273 to 429)
RR 0.72
(0.58 to
0.91)
431
(three studies)
+++-
MODERATE
Due to serious risk 
of bias and serious 
indirectness
See above truncated at 
90 days
Adverse 
events: ICU 
acquired 
weakness
298 per 1000 322 per 1000
(247 to 420)
RR 1.08
(0.83 to
1.41)
431
(three studies)
+---
VERY LOW
Due to very 
serious risk of 
bias, serious 
inconsistency 
and serious 
indirectness
Lack of robust screening 
for weakness in first two 
RCTs. Third RCT only 
assessed weakness until 
ICU discharge. Screening 
methods differed greatly 
between RCT
ARDS, acute respiratory distress syndrome; ICU, intensive care unit; NMBA, neuromuscular blocking agents; RCT, randomised controlled trial.
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suggesting a significant reduction in the risk of mortality 
with this intervention.
Although these results showed a good level of consis-
tency and precision, there are important concerns over 
the risk of bias and indirectness in the contributing RCT. 
All three studies, which were conducted by the same 
team of investigators in France, have been criticised for 
the lack of effective blinding of caregivers to study group 
allocation. In two of the studies,100 102 no attempt was 
made to blind caregivers while, in the third,101 it is ques-
tionable whether blinding was effective. It has also been 
noted that there is considerable overlap of authorship 
of the most recent SR and the contributing RCT. One 
of the contributing RCTs101 included only patients with 
severe ARDS (P/F ratio<20 kPa) within the first 48 hours, 
leading to our assessment of ‘serious’ indirectness of the 
findings for ARDS as a whole.
Length of stay
This was not reported in the included SR.
Quality of life
This was not reported in the included SR.
Economic data
This was not reported in the included SR.
Treatment harms
A key concern for the use of NMBA in ICU is the 
presumed risk of increased ICU-acquired weakness with 
their use. Although the risk of ICU-acquired weakness 
was not found to be significantly increased on MA (RR 
1.08; 95% CI 0.83 to 1.41), these findings are severely 
limited by the lack of robust screening measures in two of 
the contributing RCT,100 102 and by the lack of follow-up 
beyond ICU discharge in the final RCT101
Grade recommendation statement
We do not suggest using NMBAs for all patients with 
ARDS (GRADE Recommendation: weakly against). We 
suggest the use of cisatracurium besylate by continuous 
48 hours infusion in patients suffering early moderate/
severe ARDS (P/F<20 kPa: GRADE Recommendation: 
weakly in favour).
Grade recommendation justification
The use of cisatracurium besylate in adults suffering 
early, severe ARDS was given a weakly positive recommen-
dation based on moderate evidence quality. The group 
felt it was appropriate to recommend this management 
protocol because it was the only one studied by RCT. Due 
to the nature of this intervention, it should only be given 
to patients who are adequately sedated and receiving 
invasive ventilation. As such, it would have been difficult 
to recruit patients with mild ARDS.
Although it is reassuring that in all three RCTs the 
point estimate of treatment effect indicated a survival 
benefit, it was only by pooling these data in MA that these 
findings reached statistical significance. There are also 
concerns over the ineffective blinding of caregivers to 
study group allocation in the clinical trials and concerns 
that the potential association of NMBA and ICU-acquired 
weakness was not studied in a robust manner.
PosItIvE End-ExPIrAtory PrEssurE
PIco question
In adult patients with ARDS, does mechanical ventilation 
with higher PEEP, compared with standard (lower) PEEP 
improve survival, and selected outcomes?
study identification
The search strategy was predefined as per online appendix 
C. Six high-quality SR with MA were identified (see 
PRISMA chart in online appendix A). These used data 
from a total of seven clinical trials,92 93 103–107 published 
between 1998 and 2009. The largest single study enrolled 
983 patients.105 Data from three MA form the basis of the 
recommendation,108–110 with the most recent used where 
possible for outcomes of interest. Where this MA did not 
provide information on relevant outcomes, alternative 
MA were used.
A GRADE summary of findings table is shown based on 
critical and important outcomes (table 9). A full GRADE 
evidence table can be found as part of online appendix 
B.
Analysis of outcomes
Mortality
A MA of hospital mortality alone was presented in the 
most recent SR assessing the impact of higher PEEP in 
ARDS.110 The quality of evidence supporting the RR of 
0.90 (0.81–1.01) was deemed moderate, as there were 
different strategies used between the trials to set PEEP. 
The mean PEEP levels in each arm of the three studies 
are presented in table 10.
Mortality within 28 days of randomisation was presented 
in the same MA, and the quality of evidence supporting 
the RR of 0.83 (0.67–1.01) was low, as the analysis included 
trials which incorporated low tidal volume ventilation in 
the high PEEP arm, while the control group were venti-
lated with a low PEEP, high tidal volume strategy.
Individual patient data MA of three RCT (table 10) 
evaluating high vs low PEEP showed a reduction in 
ICU mortality (up to day 60) in patients with moderate 
or severe ARDS (P/F<27 kPa): RR 0.85 (0.76 to 0.95). 
There is moderate quality of evidence supporting this 
assessment, again because different strategies to set 
PEEP levels were used. This analysis is supported by a 
MA of three randomised trials that, with low quality of 
evidence, reported a reduced ICU mortality in patients 
with moderate or severe ARDS (RR 0.67 (0.48 to 0.95).110
Additional individual patient data MA evaluating the 
effect of high PEEP on hospital mortality in three studies 
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reported a RR 0.90 (0.81 to 1), with evidence supporting 
this finding regarded as moderate (see GRADE evidence 
profile table).108
Length of stay
In a MA of two trials, a high PEEP strategy was not asso-
ciated with a significant reduction in ICU-free days (0.04 
(95% CI −1.03 to 1.1)). This is supported by a moderate 
evidence base given the wide confidence interval that 
extends beyond the 25% threshold.
Table 9 Higher PEEP compared to lower PEEP for ARDS
Patient or population: adults with ARDS
Settings: intensive care
Intervention: higher PEEP
Comparison: lower PEEP
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect (95% 
CI)
No. of 
participants 
(studies)
Quality of 
evidence 
(GRADE) Comments
Control risk Intervention risk
Lower PEEP Higher PEEP
Mortality (hospital) 369 per 1000 332 per 1000
(299 to 373)
RR 0.90
(0.81 to 1.01)
2299
(three studies)
+++-
MODERATE
Due to serious 
inconsistency
Different 
strategies used 
to set PEEP 
between trials
Mortality (28 day) 330 per 1000 274 per 1000
(221 to 334)
RR 0.83
(0.67 to 1.01)
1921
(five studies)
++--
LOW
Due to very 
serious 
inconsistency
Includes 
studies whose 
intervention 
compares high 
vs low tidal 
volume
Subgroup analysis in 
patients with moderate/
severe ARDS (p/F<27 
kPa) (subgroup analysis)
Mortality (ICU)
561 per 1000 377 per 1000
(270 to 534)
RR 0.67
(0.48 to 0.95)
205
(three studies)
++--
LOW
Due to very 
serious 
inconsistency
Includes 
studies whose 
intervention 
compares high 
vs low tidal 
volume
Subgroup analysis in 
patients with moderate/
severe ARDS (p/F<27 
kPa) (individual patient 
data MA)
Mortality (hospital)
391 per 1000 352 per 1000
(317 to 319)
RR 0.90
(0.81 to 1)
1892
(three studies)
+++-
MODERATE
Due to serious 
inconsistency
Different 
strategies used 
to set PEEP 
between trials
Subgroup analysis in 
patients with moderate / 
severe ARDS (P/f<200)
(Individual patient data 
MA)
Mortality (ICU up to 
day 60)
366 per 1000 311 per 1000
(278 to 347)
RR 0.85
(0.76 to 0.95)
1892
(three studies)
+++-
MODERATE
Due to serious 
inconsistency
Different 
strategies used 
to set PEEP 
between trials
Adverse event: 
barotrauma
90 per 1000 87 per 1000
(59 to 127)
RR 0.97
(0.66 to 1.42)
2504
(five studies)
+---
VERY LOW
Due to very 
serious 
inconsistency 
and serious 
imprecision
Wide CI; 95% 
CI beyond 25% 
threshold
ICU free days 781 751 Mean 
difference
0.04 higher 
(1.03 lower to 
1.1 higher)
+++-
MODERATE
Due to 
imprecision
Better indicated 
by lower value 
wide CI; 95% 
CI beyond 25% 
threshold
ARDS, acute respiratory distress syndrome; ICU, intensive care unit; PEEP, positive end-expiratory pressure.
Table 10 PEEP values at day 1 in clinical trials
Study High-PEEP arm (cmH2O)
Control-group 
(cmH2O)
ALVEOLI105 14.7±3.5 8.9±3.5
LOV 105 15.6±3.9 10.1±3.1
ExPRESS106 14.6±3.2 7.1±1.8
Values are mean+SD.
PEEP, positive end-expiratory pressure.
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Quality of life
This was not reported in the included SRs.
Economic data
This was not reported in the included SRs.
Treatment harms
A higher PEEP ventilation strategy was not associated 
with increased rates of air leaks (RR 0.97 (0.66 to 1.42)), 
with the evidence supporting this finding deemed very 
low because of the difference in tidal volume strategies 
assessed between the intervention and control arms of 
some studies, and the imprecision of the results.110
Grade recommendations
We suggest the use of high PEEP strategies for patients 
with moderate or severe ARDS (P/F ratio <27 kPa: 
GRADE Recommendation: weakly in favour).
Grade justification
We identified low-quality evidence to support the use of 
higher PEEP strategies in the ventilation of patients with 
moderate or severe ARDS. Evidence was downgraded 
because of inconsistency caused by differences between 
individual studies in the strategy to set the level of PEEP, 
while some trials compared lower tidal volume venti-
lation as part of a ventilator strategy that incorporated 
higher PEEP levels. The recommendation to consider 
the use of higher PEEP in patients with at least moderate 
ARDS is based on subgroup and individual patient data 
MA, providing less robust evidence than a RCT inves-
tigating higher PEEP in this patient group. The risk of 
barotrauma as a result of the use of higher PEEP for 
patients with at least moderate or severe ARDS cannot be 
excluded because this risk has not been quantified in this 
population. The quality of this evidence is also limited by 
inconsistency as the MA included trials of high PEEP with 
different tidal volume strategies.
PronE PosItIonInG
PIco question
In adults with ARDS, does the use of prone positioning, 
compared with standard care, affect survival and selected 
outcomes?
study identification
The search strategy was predefined as per online appendix 
C. Fourteen eligible SRs investigating the effect of prone 
positioning in ARDS98 111–123 (see PRISMA chart in online 
appendix A) were identified. Twelve reviews included 
a MA.98 111–113 115 117–123 The most recently published of 
these was used for data extraction.120
A GRADE Summary of Findings table is shown based 
on available evidence for critical and important outcomes 
(table 11). A full GRADE evidence table can be found as 
part of online appendix B.
Analysis of outcomes
Mortality
Mortality (defined as overall mortality at the longest 
available follow-up) was significantly reduced with prone 
positioning (RR 0.9; 95% CI 0.82 to 0.96, 8 studies, 2141 
patients) with very low quality of evidence supporting this 
RR. All trials demonstrated performance bias, because 
of the impossibility of blinding patients and carers with 
respect to the intervention. All trials also demonstrated 
detection bias, where outcome assessors were not blinded 
to intervention allocation. One RCT additionally demon-
strated selection bias124 and three separate trials suffered 
from attrition bias125–127 according to the Cochrane risk of 
bias recommendations.128 Inconsistency was very serious, 
with varied point estimates, overlapping confidence inter-
vals with high and significant levels of heterogeneity. There 
was also serious indirectness as the cohort of trials included 
subgroups receiving additional interventions known to 
demonstrate a mortality benefit.
Subgroup analysis demonstrated that prone positioning 
in combination with lung-protective ventilation (low tidal 
volume ventilation, 6–8 mL/kg body weight) demonstrated 
a significant reduction in mortality (RR 0.73; 95% CI 0.62 to 
0.86) compared with patients receiving prone positioning 
and no lung-protective ventilation (RR 1.01; 95% CI 0.9 to 
1.13), supported by moderate quality evidence. These find-
ings may be influenced by inclusion of one trial enrolling a 
sizeable patient cohort with more severe ARDS (P/F ratio 
<20 kPa, FiO2>0.6)
129 which showed larger differences 
in mortality rates between patients managed prone and 
supine in the setting of lung-protective ventilation.
Subgroup analysis based on the duration of prone posi-
tioning found that over 12 hours of prone positioning was 
associated with significantly reduced mortality (>12 hour, 
RR 0.75, 95% CI 0.65 to 0.87;<12 hour, RR 1.03, 95% CI 0.91 
to 1.17), again supported by moderate quality evidence.
Length of stay
ICU length of stay was only examined in two older MAs.112 123 
However, these data could not be extracted, as pooled anal-
yses included either confirmed or potential paediatric data. 
No other trial examined hospital length of stay.
Quality of life
No trial reported on health-related quality of life.
Economic data
No trial reported on economic data.
Treatment harms
Overall, the pooled risk of any adverse event with prone 
positioning was significantly increased (RR 1.10; 95% CI 
1.01 to 1.12). Where a more detailed analysis of adverse 
events was conducted, endotracheal tube displacement 
(RR 1.33; 95% CI 1.02 to 1.74), the incidence of pressure 
sores (1.23; 95% CI 1.07 to 1.41) and loss of venous access 
(RR 1.98; 95% CI 1.11 to 3.55) were significantly increased. 
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Table 11 Prone positioning compared with standard care for ARDS
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect 
(95% CI)
No. of 
participants 
(studies)
Quality of 
evidence (GRADE) Comments
Control risk Intervention risk
Standard Care Prone Positioning
Mortality (pooled) 467 per 1000 421 per 1000
(383 to 458)
RR 0.90
(0.82 to 
0.98)
2141
(eight studies)
+---
VERY LOW
Due to serious risk 
of bias, very serious 
inconsistency and 
serious indirectness
Failure to blind outcome, failure of 
allocation concealment, and incomplete 
outcome data
Includes sub-groups receiving 
additional interventions known to 
demonstrate a potential mortality 
benefit
Subgroup 
analysis
Prone positioning 
with lung 
protective 
ventilation
Mortality
447 per 1000 326 per 1000
(277 to 384)
RR 0.73
(0.62 to 
0.86)
910
(five studies)
+++- MODERATE
Due to serious risk 
of bias
Failure to blind outcome, failure of 
allocation concealment, and incomplete 
outcome data
Subgroup 
analysis
Prone positioning 
without lung 
protective 
ventilation
Mortality
483 per 1000 488 per 1000
(435 to 546)
RR 1.01
(0.9 to 
1.13)
1231
(three studies)
+++- MODERATE
Due to serious risk 
of bias
See above
Subgroup 
analysis
Prone positioning 
for more than 12 
hours
Mortality
479 per 1000 359 per 1000
(311 to 416)
RR 0.75
(0.65 to 
0.87)
1006
(five studies)
+++- MODERATE
Due to serious risk 
of bias
See above
Subgroup 
analysis
Prone positioning 
for less than 12 
hours
Mortality
457 per 1000 471 per 1000
(416 to 535)
RR 1.03
(0.91 to 
1.17)
1135
(three studies)
+++- MODERATE
Due to serious risk 
of bias
See above
Adverse events 
(pooled)
188 per 1000 207 per 1000
(190 to 226)
RR 1.10
(1.01 to 
1.2)
7377
(seven studies)
+---
VERY LOW
Due to serious 
risk of bias and 
very serious 
inconsistency
Failure to blind outcome, failure of 
allocation concealment, and incomplete 
outcome data
Adverse events: 
cardiac events
278 per 1000 281 per 1000
(242 to 325)
RR 1.01
(0.87 to 
1.17)
1599
(three studies)
+---
VERY LOW
Due to serious 
risk of bias and 
very serious 
inconsistency
Failure to blind outcome, failure of 
allocation concealment, and incomplete 
outcome data
Cohort includes subgroups receiving 
additional interventions known to 
demonstrate a potential mortality 
benefit for example, lung- protective 
ventilation
Adverse events: 
endotracheal 
tube 
displacement
101 per 1000 134 per 1000
(103 to 176)
RR 1.33
(1.02 to 
1.74)
1597
(five studies)
++--
LOW
Due to serious risk 
of bias and serious 
imprecision
See above
Adverse events: 
ventilator-
associated 
pneumonia
248 per 1000 218 per 1000
(176 to 270)
RR 0.88
(0.71 to 
1.09)
1007
(four studies)
++--
LOW
Due to serious risk 
of bias and serious 
imprecision
See above
Adverse events: 
pressure sores
375 per 1000 462 per 1000
(402 to 529)
RR 1.23
(1.07 to 
1.41)
1095
(two studies)
++--
LOW
Due to serious risk 
of bias and serious 
imprecision
See above
Continued
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However, this evidence was down-graded based on the risk 
of bias and imprecision in the trials evaluated.
Grade recommendation statement
We do not recommend the use of prone positioning for 
all patients with ARDS. We recommend the use of prone 
positioning for at least 12 hours per day in patients with 
moderate/severe ARDS (P/F ratio<20 kPa: GRADE recom-
mendation: strongly in favour).
Grade recommendation justification
Current evidence includes the possibility of substan-
tial patient benefit in terms of reduced mortality 
when combined with lung-protective ventilation and 
when delivered for at least 12 hours to patients with 
moderate/severe ARDS. Evidence for these findings 
was of moderate quality. The GDG noted the relative 
improvements in study design over the time course of 
publication of all eight trials, such that the most recently 
published focused enrolment on the most severe strata 
of patients with ARDS, and involved a multimodal inter-
vention comprising lung-protective ventilation with 
prolonged prone positioning producing highly favour-
able outcomes.129 This observation provides the rationale 
for the strong classification of recommendation.
The possibility for substantial patient benefit must 
be considered in the context of a significant risk of 
occurrence of adverse events including endotracheal 
tube displacement, pressure sores and loss of venous 
access, although the evidence to support these findings 
was either low or very low. However, the GDG felt that 
these adverse events could be mitigated by ensuring that 
sufficient skilled personnel were in place to deliver and 
monitor the intervention.
conclusIon
summary
Table 12 outlines the GDG’s synthesis of data for the 
Management of ARDS from relevant clinical trials.
dIscussIon
The summary of the group’s recommendations empha-
sises the importance of avoiding VALI in patients with 
ARDS, as all of the interventions with positive recom-
mendations apart from maintaining a conservative fluid 
balance, arguably act through this process. Despite at 
best moderate quality evidence by MA, we have strongly 
supported the use of low tidal volume and low airway 
pressure mechanical ventilation. This ventilation strategy 
is supported by results of the ARDS Network ARMA 
study,87 data from studies whose primary outcome was 
the prevention of ARDS and a large volume of evidence 
from preclinical and mechanistic studies. It is now so 
universally accepted that it is mandated for all patients 
in clinical trials of ARDS. When applied to patients 
with moderate/severe ARDS for at least 12 hours per 
day, prone positioning was also strongly recommended 
because the most recent studies focused enrolment on 
the most severe strata of patients with ARDS and involved 
a multimodal intervention comprising lung-protective 
ventilation with prolonged prone positioning producing 
highly favourable outcomes.129 By contrast, despite a 
strong theoretical rationale as a means of preventing 
VALI, high frequency oscillatory ventilation was inef-
fective or deleterious in two large studies leading to our 
recommendation strongly against its use.
While broadly similar recommendations for the 
management of ARDS have been produced, many ques-
tions remain. Fundamentally the parameters charac-
terising optimal protective mechanical ventilation are 
unknown, as are the optimal means of achieving them. 
We have recommended targeting <6 mL/kg ideal body 
weight (IBW), but, based on the absence of evidence of 
a safe tidal volume threshold on retrospective reanalysis 
of the ARMA study130 and a dose-response effect seen 
in observational studies,131 it would be reasonable to 
recommend minimising tidal volume as far as possible. 
Similarly, analysing individual patient data from RCT 
concluded that driving pressure (plateau pressure minus 
PEEP) was a better predictor of outcome than tidal 
volume or plateau pressure alone.132 Finally, there is no 
Outcomes
Illustrative comparative risks (95% CI)
Relative 
effect 
(95% CI)
No. of 
participants 
(studies)
Quality of 
evidence (GRADE) Comments
Control risk Intervention risk
Standard Care Prone Positioning
Adverse events: 
pneumothorax
67 per 1000 58 per 1000
(40 to 87)
RR 0.87
(0.59 to 
1.30)
1160
(four studies)
++--
LOW
Due to serious risk 
of bias and serious 
imprecision
See above
Adverse events: 
loss of venous 
access
49 per 1000 97 per 1000
(54 to 174)
RR 1.98
(1.11 to 
3.55)
646
(two studies)
+---
VERY LOW
Due to serious risk 
of bias, very serious 
inconsistency and 
serious imprecision
See above
Table 11 Continued
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consensus regarding the means used to optimise PEEP 
(oxygenation or various lung mechanical parameters) 
or to manage the respiratory acidosis that commonly 
accompanies protective ventilation.
In certain details, recent guidelines have diverged. 
We felt that the evidence supporting the role of recruit-
ment manoeuvres was so poor and the concept so ill-de-
fined that we were unable to make a recommendation. 
By contrast, the American Thoracic Society/European 
Society of Intensive Care Medicine/Society of Critical 
Care Medicine group has given a conditional recommen-
dation, although with low-to-moderate confidence.5 Simi-
larly, our group did not consider airway pressure release 
ventilation owing to the paucity of high quality, relevant 
evidence, despite the knowledge that this ventilatory 
mode is widely used. Hopefully there will be sufficient 
evidence to justify including these interventions in the 
next version of the guidelines.
We have synthesised available evidence with the clin-
ical practice of the GDG into a management algo-
rithm (figure 1). Hence, for a patient presenting with 
for example severe ARDS, low tidal volume (<6 ml/kg 
IBW) and low plateau pressure (<30 cmH2O), mechan-
ical ventilation using higher PEEP is recommended with 
the addition of neuromuscular blockade for the first 48 
hours and prone positioning for at least 12 hours per 
day. After initial resuscitation of the circulation, a neutral 
or, if tolerated, a negative fluid balance target should be 
set. Consideration of escalation to extracorporeal lung 
support (ECMO or ECCO2R) is indicated by the failure 
to achieve adequate gas exchange using protective venti-
latory settings as described above. To what extent is this 
synthesis evidence-based? While the individual compo-
nents are to an extent evidence-based, the combination 
of interventions has evolved rather than being formally 
tested. For example, attempts have been made to test 
a so-called ‘open lung approach', by combining higher 
PEEP levels with low tidal volume ventilation both in early 
studies concentrating on low tidal volume ventilation, 
in subsequent PEEP trials and more recently in studies 
combining the use of recruitment manoeuvres and high 
levels of PEEP. The rationale for the open lung approach 
is that increasing airway pressure will increase the volume 
of ventilatable lung, thereby decreasing VALI and a large 
clinical trial was supported by encouraging pilot data. 
This Alveolar Recruitment for Acute Respiratory Distress 
Syndrome Trial (ART) carried out in 1010 patients with 
severe ARDS surprisingly showed significantly higher 
6-month mortality (65.3% vs 59.9%) in the intervention 
group.133 These data demonstrate the enduring value of 
large well-conducted clinical trials of complex interven-
tions in this challenging patient group.
unmEt nEEds, rEsEArch And FuturE dIrEctIons
We have made research recommendations for two inter-
ventions for adult patients with ARDS: corticosteroids and 
ECCO2R. Two international studies are currently exam-
ining the effects of ECCO2R combined with ultralow tidal 
volume ventilation (pRotective vEntilation with Veno-ve-
nouS Lung Assi (pRotective vEntilation With Veno-ve-
nouS Lung assisT in Respiratory Failure (REST,  Clinical-
Trials. gov NCT02654327) and SUPERNOVA: A Strategy 
of UltraProtective lung ventilation with Extracorporeal 
CO2 Removal for New-Onset moderate to seVere ARDS, 
whose pilot study has just been reported.
There are no disease modifying, drug therapies for 
ARDS. Drug development in this area is notoriously 
Table 12 Summary of the FICM/ICS Guidelines for the management of ARDS in adult patients
Topic
GRADE
recommendation Conditions
Tidal volume Strongly in favour Tidal volume <6 mL/kg ideal body weight; Plateau pressure < 30 
cmH2O
Prone positioning Strongly in favour Proning for >12 hours per day
Patients with moderate/severe ARDS (P:F ratio < 20 kPa)
HFOV Strongly against
Conservative fluid management Weakly in favour
Higher PEEP Weakly in favour Patients with moderate or severe ARDS (PF ratio <27 kPa)
NMBA Weakly in favour Evidence only for cisatracurium besylate
Continuous 48 hours infusion
Patients with moderate/severe ARDS (<20 kPa)
ECMO Weakly in favour With lung-protective mechanical ventilation
Patients with severe ARDS, lung injury score >3 or pH <7.20 due to 
uncompensated hypercapnoea
Inhaled vasodilators Weakly against Evidence only for inhaled nitric oxide
Corticosteroids Research recommendation
ECCO2R Research recommendation
ARDS, acute respiratory distress syndrome; ECCO2R, extracorporeal carbon dioxide removal; ECMO, extracorporeal membrane oxygenation; FICM, 
Faculty of Intensive Care Medicine; HFOV, high frequency oscillation; ICS, Intensive Care Society; NMBA, neuromuscular blocking agents; PEEP, 
peek end-expiratory pressure.
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difficult, partly because ARDS is not a disease but a 
syndrome describing acute respiratory failure occurring 
de novo as a result of a wide variety of conditions. One 
strategy designed to increase the likelihood of positive 
clinical trials in ARDS is to select a less heterogeneous 
patient population—a step on the road to a personalised 
approach made at the expense of having a smaller pool 
of patients from which to recruit. Such splitting can be 
envisaged on the basis of readily identifiable predisposing 
causes (eg, influenza pneumonia, transfusion-related 
acute lung injury (TRALI) or systemic sepsis) or inherent 
patient characteristics, such as alcoholism or the expres-
sion of particular single nucleotide polymorphisms 
known to be associated with a predisposition to ARDS. 
The ultimate aim is to identify subgroups, so-called endo-
types of ARDS that will predict a positive response to a 
certain class of therapy.134
Current management of ARDS is hampered by failure to 
diagnose the condition and to prevent iatrogenic harms. 
We need to heighten awareness of the diagnosis, partic-
ularly outside ICU, so that the opportunity to prevent 
progression of the syndrome is not missed. Research into 
prevention and treatment needs to be translated more 
effectively into the clinic. Biomarkers that confirmed the 
diagnosis highlighted patients with a poor prognosis and 
predicted that a positive response to a particular therapy 
would be invaluable in research and clinical care. For 
example, a validated bedside biomarker of VALI would 
facilitate the fine tuning of mechanical ventilation and 
could guide related decisions during the recovery phase 
of ARDS, for example, assessing the risk-benefit relation-
ship between allowing spontaneous ventilatory modes 
with associated larger tidal volumes.
In order to discover effective drug therapies, continued 
investment in human studies that aim to elucidate the 
pathogenesis of ARDS is essential to identify clinically 
useful biomarkers and surrogate outcome measures.135 136 
These investigations need to be performed with a view to 
designing a stepwise approach to testing novel therapeu-
tics in this particularly challenging patient group.137
Finally, standardisation of outcome measures will help 
in the conduct and comparison of clinical trials and such 
work is underway, for example, the Core Outcomes for 
Ventilation Trials: the COVenT Delphi study (COMET 
registration: http://www. comet- initiative. org/ studies/ 
details/ 292). As reflected in the outcome prioritisation 
exercise carried out by the GDG, there is an increasing 
emphasis on the health of survivors of critical illness, 
which mandates that clinical trials include long-term 
outcomes and economic analysis that will inform the soci-
etal impact of intensive care medicine.
mAnAGEmEnt oF Ards In PrActIcE
management
The essence of management of ARDS consists of opti-
mising the diagnosis and treatment of underlying condi-
tions, and the deployment of supportive measures that 
minimise iatrogenic injury and the consequences of 
severe critical illness (ie, secondary and tertiary preven-
tion). We have combined these strategies with the 
outcome of the analysis of evidence relating to the topics 
selected in figure 3.
Primary prevention
A common theme of research into critical illness has been 
the increasing appreciation of the contribution of iatro-
genic factors, most notably: fluid overload, VALI from 
mechanical ventilation, transfusion of blood products 
and hospital acquired infection.138 While it is sobering to 
appreciate the negative role that healthcare systems have 
played, it has at least indicated the potential to prevent 
ARDS through simple quality improvement interven-
tions.139 140 Similarly, while causes of ARDS that act directly 
on the lung, including pneumonia and gastric aspiration, 
are associated with a rapid progression to ARDS, indirect 
causes typified by severe sepsis commonly evolve into 
ARDS as part of a multiorgan dysfunction syndrome over 
2–4 days.14
Scoring systems have been developed to predict 
progression to ARDS both in patients at risk and those 
with early lung injury. The Lung Injury Prediction Score 
(LIPS: table 13) is the product of a series of epidemiolog-
ical studies.141 142 LIPS was designed to identify a popu-
lation of patients at high risk of ARDS for prevention 
studies to be carried out by the National Institutes of 
Health’s Prevention and Early Treatment of Acute Lung 
Injury (PETAL) Network (http:// petalnet. org/). LIPS-A 
was a large multicentre study to address the question 
of whether ARDS can be prevented with a drug, in this 
case aspirin, the latest in a succession of promising ther-
apeutics for ARDS, which was supported by a plethora 
of positive preclinical data. Disappointingly, the study 
was negative and one contributing factor was that the 
score threshold for study inclusion produced only half 
the predicted number of ARDS cases, the study’s primary 
outcome.143 This raises concerns about the ability of LIPS 
to identify an enriched population of patients at risk for 
ARDS without the addition of factors such as biomarkers 
that can predict deterioration from at risk, to mild, to 
severe ARDS, and to death. Similarly, by characterising 
patients early in their clinical course before they develop 
ARDS, it has been possible to refine the parameters to 
the need for supplemental oxygen, an elevated respira-
tory rate and bilateral infiltrates on the chest radiograph 
to identify patients with early acute lung injury (EALI).144 
Validation by means of a multicentre study prospec-
tively evaluating the positive predictive value of a score 
comprising these variables would be required to generate 
a EALI score that could have a similar role to LIPS in 
future trials.
secondary and tertiary prevention
Transfusion of blood products has been associated 
with the incidence of ARDS, nosocomial infection and 
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mortality in critical illness. TRALI is defined as the 
onset of ARDS within 6 hours of the transfusion of any 
blood product in the absence of another risk factor.145 
The most important mechanism of injury appears to be 
the interaction of preformed antibodies in the product 
with the host pulmonary vascular endothelium. Hence, 
products containing the most plasma confer the highest 
risk and the exclusion of female donors of products with 
high plasma volume has resulted in a decrease of roughly 
two-thirds in the incidence of TRALI. Transfusion of 
packed red cells using a threshold of 7 was non-inferior 
to a threshold of 9 g/dL and corresponding protocols 
Figure 3 Analysis of evidence relating to the topics selected in this figure. ARDS, acute respiratory distress syndrome; CPAP, 
continuous positive airway pressure; ECMO, extracorporeal membrane oxygenation; PEEP, positive end-expiratory pressure.
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restricting unnecessary transfusion should be introduced 
locally and practices audited.
There is a lack of evidence-based practices that decrease 
hospital acquired infection. An effective local antibi-
otic policy should aim to optimise antibiotic treatment 
according to local surveillance data and to ensure rapid 
de-escalation based on culture results. Recent evidence 
suggests that enteral nutrition is preferable to parenteral, 
and that underfeeding is less dangerous than overpro-
vision. Finally, active rehabilitation, specialist outpatient 
follow-up and psychological support have been recom-
mended for all survivors of severe critical illness in order 
to mitigate the associated neuropsychological effects and 
weakness.146
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Table 13 The lung injury prediction score
Predisposing conditions
LIPS
Score Examples
Shock 2 (1) Patient with history of alcohol abuse with septic shock from 
pneumonia requiring FiO2>0.35
Emergency room: sepsis+shock+pneumonia+alcohol 
abuse+FiO2>0.35
1+2+1.5+1+2=7.5
(2) Motor vehicle accident with traumatic brain injury, lung 
contusion and shock requiring FiO2>0.35
Traumatic brain injury+lung contusion+shock+FiO2>0.35
2+1.5+2+2=7.5
(3) Patient with history of diabetes mellitus and urosepsis with 
shock sepsis+shock+diabetes
1+2–1=2
Aspiration 2
Sepsis 1
Pneumonia 1.5
High-risk surgery*
Orthopaedic spine 1
Acute abdomen 2
Cardiac 2.5
Aortic vascular 3.5
High-risk trauma
Traumatic brain injury 2
Smoke inhalation 2
Near drowning 2
Lung contusion 1.5
Multiple fractures 1.5
Risk modifiers
Alcohol abuse 1
Obesity (BMI>30) 1
Hypoalbuminaemia 1
Chemotherapy 1
FiO2 >0.35 (>4 L/min) 2
Tachypnoea (RR>30) 1.5
SpO2 <95% 1
Acidosis (pH<7.35) 1.5
Diabetes mellitus† -1
*Add 1.5 points in case of emergency surgery.
†Only in cases of sepsis.
BMI, body mass index; RR, respiratory rate; SpO2, oxygen saturation by pulse oximetry.
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